Although clinical trials in patients with heart failure with preserved ejection fraction with pirfenidone, a TGFβ inhibitor approved for idiopathic pulmonary fibrosis, are ongoing [19], it remains to be established whether these drugs confer an additional anti-fibrotic benefit over ACEIs or ARB [20]. This evidence concerns the gene TGFB1 and idiopathic pulmonary fibrosis.